Nippon India Pharma IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

Nippon India Pharma IDCW Reinvest Direct Plan

NAV
₹182.1688
-0.90%
(20 Dec)
AUM
8,638 Cr
TER
0.91%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+37.1%
+36.5%
+36.5%
+36.5%
+35.4%
3Y
+23.1%
+38.6%
+38.6%
+38.6%
+36.8%
5Y
+30.9%
+25.7%
+25.7%
+25.7%
+28.8%
ALL
+20.6%
+12.3%
+12.3%
+12.3%
+17.3%
VOL
17.1%
20.3%
20.3%
20.3%
20.0%
TER
0.9%
0.7%
0.7%
0.7%
0.8%
AUM
₹8,638 Cr
₹4,686 Cr
₹4,686 Cr
₹4,686 Cr
₹1,345 Cr
INFO
1.20
0.61
0.61
0.61
0.86
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Nippon India Pharma IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Nov
Top holdings
Sun Pharmaceuticals Industries Ltd
13.5%
Divi's Laboratories Ltd
9.7%
Lupin Ltd
7.6%
Cipla Ltd
5.5%
Apollo Hospitals Enterprise Ltd
5.1%
Dr Reddy's Laboratories Ltd
5.1%
Vijaya Diagnostic Centre Ltd
4.1%
Ajanta Pharma Ltd
3.4%
Medplus Health Services Ltd
3.2%
Triparty Repo
3.2%
Top industry exposure
Healthcare
96.5%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
12%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
Fund manager(s)
Sailesh Raj Bhan
Kinjal Desai

FAQs